SGS introduces new comprehensive drug compatibility study testing at expanded Shanghai facility
![](/46/pdcnewsitem/04/13/59/SGS.png)
New service offers analysis of potential extractable and leachable contamination within pharmaceutical products.
SGS has introduced comprehensive drug compatibility study testing at its Shanghai laboratory in China. This new service, for the analysis of potential extractable and leachable contamination within pharmaceutical products, harmonizes services offered in this field across SGS’s global network of laboratories.
China’s Center for Drug Evaluation (CDE) made drug compatibility studies mandatory for all New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) in 2014. SGS’s investment in these services comes after a multi-stage expansion of its laboratory in Shanghai, which was completed in 2015. It includes the installation and validation of new quadrupole time-of-flight (Q-TOF), liquid chromatography-diode array-mass spectrometry (LC-DAD-MS) and gas chromatography–mass spectrometry (GC-MS) instruments.
“We have seen an increased demand for these services since the regulations have been tightened, and we have been working with regulatory bodies and industry associations to help define and establish definitive testing guidelines in this area going forward,” commented Andy Yi, General Manager, SGS Life Sciences, Shanghai. “With this investment, SGS has been able to build on its strong reputation to attract new customers, as well as increase business with pharmaceutical R&D teams looking to engage with experts earlier in the process to ensure compliance.”
SGS has been providing extractable and leachable testing services from its Shanghai facility to local clients, and international clients with a presence in China since the facility opened in 2006. Expansion of the facility commenced in 2014 and initially included increased capabilities in cGMP chemistry and biotechnology testing laboratories. The microbiology laboratory was expanded subsequently, increasing the total floor space to 3,200 m2.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance